CORDIS
EU research results

CORDIS

English EN
EUROpean consortium on NEUTralising antibodies using gp41

EUROpean consortium on NEUTralising antibodies using gp41

Objective

There is now an increasingly solid body of scientific evidence which demonstrates that the binding of small molecular weight compounds, peptides and antibodies (Abs) to fusion-intermediate conformations of gp41 leads to an inhibition of HIV cell entry. The principal aim of this project is to exploit this information by establishing a platform where gp41-derived vaccine candidates will be designed to elicit neutralising Abs. Several families of immunogens which mimic gp41 in its fusion intermediate conformations are already available and others will be designed using modelisation approaches. Candidates will be submitted to a thorough biophysical characterisation followed by a preclinical development in order to identify the most promising for clinical evaluation. A crucial selection parameter is the capacity of antigens to elicit neutralising Abs using internationally standardized assays. Since sexual transmission accounts for more than 90% of HIV infection, the capacity of Abs to inhibit infection at the mucosal level will also be determined. This cross-disciplinary project gathers top European scientists with expertise in protein engineering and characterisation, adjuvantation, formulation for systemic and mucosal delivery, evaluation of functional antibody response, efficacy testing in animal models, medium to large scale vaccine production as well as conduct of clinical trials in both developed and third-world countries. In contrast to previous more empirical attempts, this project is based on the rational exploitation of the knowledge on the mechanism of HIV entry and is thus a promising approach to generate a protective vaccine. It will be the first European project targeting intermediate conformations of gp41 and it could complement/synergize other international strategies focusing on the membrane proximal region of gp41 or gp140 trimer to induce neutralising Abs or aiming at reducing the viral load by eliciting a cellular immunity against HIV.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

SANOFI PASTEUR SA

Address

Avenue Pont Pasteur, 2
69007 Lyon

France

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 1 067 425,58

Administrative Contact

Delphine Jullien

Participants (18)

Sort alphabetically

Sort by EU Contribution

Expand all

ROBERT KOCH-INSTITUT

Germany

EU Contribution

€ 750 871,56

UNIVERSIDAD DE GRANADA

Spain

EU Contribution

€ 976 782,10

GENEART AG

Germany

EU Contribution

€ 284 464,80

BIONEER A/S

Denmark

EU Contribution

€ 285 617,76

PX'Therapeutics

France

EU Contribution

€ 1 429 475,64

THE QUEEN'S UNIVERSITY OF BELFAST

United Kingdom

EU Contribution

€ 494 606,50

POLYMUN SCIENTIFIC IMMUNBIOLOGISCHE FORSCHUNG GMBH

Austria

EU Contribution

€ 573 602,80

NEMZETI ELELMISZERLANC-BIZTONSAGI HIVATAL

Hungary

EU Contribution

€ 146 950

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

France

EU Contribution

€ 1 671 433,70

ST GEORGE'S HOSPITAL MEDICAL SCHOOL

United Kingdom

EU Contribution

€ 469 854,26

ROYAL FREE LONDON NHS FOUNDATION TRUST

United Kingdom

EU Contribution

€ 233 145,10

LES CENTRES GHESKIO

Haiti

EU Contribution

€ 18 029

IM PROJET (SUISSE) SARL

Switzerland

UNIVERSITE DE STRASBOURG

France

EU Contribution

€ 1 199 583,42

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 174 250,80

IM PROJET SAS

France

EU Contribution

€ 585 382,40

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom

EU Contribution

€ 779 270,58

UNIVERSITY OF SURREY

United Kingdom

EU Contribution

€ 825 336

Project information

Grant agreement ID: 201038

Status

Closed project

  • Start date

    1 January 2008

  • End date

    31 March 2014

Funded under:

FP7-HEALTH

  • Overall budget:

    € 15 922 033,23

  • EU contribution

    € 11 966 082

Coordinated by:

SANOFI PASTEUR SA

France